Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps.

OBJECTIVE To study the reproducibility of plasma insulin kinetics during intraperitoneal (IP) insulin therapy using an implanted programmable pump in patients with type 1, insulin dependent, diabetes mellitus (IDDM). RESEARCH DESIGN AND METHODS In a group of ten type 1 IDDM patients beginning chronic IP insulin treatment with an implanted pump, plasma free insulin profiles were determined from 12: 00 am to 12: 30 pm on two separate test days, one month apart. Anti-insulin antibody (AIA) levels were measured on each test day. RESULTS From test day 1 to test day 2, no difference was observed in morning fasting free insulin levels (m +/- SD): 9.7 +/- 5.4 mU/L versus 9.8 +/- 5.3 mU/L, insulin peak values: 19.1 +/- 17 mU/L versus 20.8 +/- 9.9 mU/L, time to peak: 40 +/- 15 versus 42.8 +/- 16 minutes or post-bolus area under the plasma free insulin curve (AUC): 40.7 +/- 29 mU/L.h versus 45.5 +/- 29 mU/L.h. The intrapatient coefficient of variation was 14.4 +/- 13% for insulin peaks and 16.9 +/- 9.2% for post-bolus AUC. A significant increase in AIA levels (m +/- SD) was observed from 16.5 +/- 18% on test day 1 to 28.1 +/- 28% on test day 2. CONCLUSIONS The reproducibility of plasma free insulin profiles is highly satisfactory during insulin delivery by the IP route using an implanted device.

[1]  R. Wredling,et al.  Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion. , 1991, Diabete & metabolisme.

[2]  J. Lutterman,et al.  Insulin Antibodies do not Influence the Absorption Rate of Subcutaneously Injected Insulin , 1988, Diabetic medicine : a journal of the British Diabetic Association.

[3]  N. Jeandidier,et al.  French multicentre experience of implantable insulin pumps , 1994, The Lancet.

[4]  A. Caumo,et al.  Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects. , 1993, The Journal of clinical endocrinology and metabolism.

[5]  E. Renard,et al.  Decreased Severe Hypoglycemia Frequency During Intraperitoneal Insulin Infusion Using Programmable Implantame Pumps , 1996, Diabetes Care.

[6]  D. Raccah,et al.  Insulin Kinetics in Type I Diabetic Patients Treated by Continuous Intraperitoneal Insulin Infusion: Influence of Anti‐insulin Antibodies , 1996, Diabetic Medicine.

[7]  E. Renard,et al.  Feasibility of Intraperitoneal Insulin Therapy With Programmable Implantable Pumps in IDDM: A multicenter study , 1995, Diabetes Care.

[8]  H. Pitt,et al.  A preliminary trial of the programmable implantable medication system for insulin delivery. , 1989, The New England journal of medicine.

[9]  D. Nathan,et al.  Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. , 1996, The American journal of medicine.

[10]  K. Mashimo,et al.  A Simple Method for the Determination of Serum Free Insulin Levels in Insulin-treated Patients , 1973, Diabetes.

[11]  J. Gerich,et al.  Adverse Effects of Insulin Antibodies on Postprandial Plasma Glucose and Insulin Profiles in Diabetic Patients Without Immune Insulin Resistance: Implications for Intensive Insulin Regimens , 1987, Diabetes.

[12]  N. Wong,et al.  Insulin Antibody Responses After Long-Term Intraperitoneal Insulin Administration via Impiantatile Programmable Insulin Delivery Systems , 1994, Diabetes Care.

[13]  G. Bolli.  The pharmacokinetic basis of insulin therapy in diabetes mellitus. , 1989, Diabetes research and clinical practice.

[14]  Point Study Group.  ONE-YEAR TRIAL OF A REMOTE-CONTROLLED IMPLANTABLE INSULIN INFUSION SYSTEM IN TYPE I DIABETIC PATIENTS , 1988, The Lancet.

[15]  R. Arakaki,et al.  Prolonged action of regular insulin in diabetic patients: lack of relationship to circulating insulin antibodies. , 1986, The Journal of clinical endocrinology and metabolism.

[16]  Pharmacokinetics of insulin infused intra-peritoneally via portable pumps. , 1985, Diabete & metabolisme.

[17]  N. Jeandidier,et al.  Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices , 1995, Diabetologia.

[18]  D. Raccah,et al.  Immunogenicity of Long-Term Intraperitoneal Insulin Administration With Implantable Programmable Pumps: Metabolic consequences , 1995, Diabetes Care.

[19]  O Faber,et al.  Insulin Pharmacokinetics , 1984, Diabetes Care.

[20]  E. Renard,et al.  Decreased severe hypoglycemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Evadiac Study Group. , 1996, Diabetes Care.

[21]  G. Pozza,et al.  Intraperitoneal Insulin Absorption After Lona-Term Intraperitoneal Insulin Therapy , 1995, Diabetes Care.

[22]  R. P. Eaton,et al.  Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man , 1980, Diabetologia.

[23]  K. Alberti,et al.  Free insulin levels and metabolic effects of meal-time bolus and square-wave intraperitoneal insulin infusion in insulin-dependent diabetic patients , 1985, Diabetologia.

[24]  G. Bolli,et al.  Insulin analogues and their potential in the management of diabetes mellitus , 1999, Diabetologia.